全文获取类型
收费全文 | 793篇 |
免费 | 120篇 |
国内免费 | 3篇 |
专业分类
耳鼻咽喉 | 5篇 |
儿科学 | 56篇 |
妇产科学 | 17篇 |
基础医学 | 104篇 |
口腔科学 | 34篇 |
临床医学 | 153篇 |
内科学 | 174篇 |
皮肤病学 | 16篇 |
神经病学 | 41篇 |
特种医学 | 51篇 |
外科学 | 60篇 |
综合类 | 23篇 |
预防医学 | 90篇 |
眼科学 | 10篇 |
药学 | 32篇 |
肿瘤学 | 50篇 |
出版年
2023年 | 17篇 |
2021年 | 14篇 |
2020年 | 8篇 |
2019年 | 12篇 |
2018年 | 27篇 |
2017年 | 12篇 |
2016年 | 14篇 |
2015年 | 15篇 |
2014年 | 28篇 |
2013年 | 37篇 |
2012年 | 27篇 |
2011年 | 23篇 |
2010年 | 32篇 |
2009年 | 45篇 |
2008年 | 31篇 |
2007年 | 20篇 |
2006年 | 19篇 |
2005年 | 26篇 |
2004年 | 26篇 |
2003年 | 20篇 |
2002年 | 20篇 |
2001年 | 16篇 |
2000年 | 23篇 |
1999年 | 30篇 |
1998年 | 30篇 |
1997年 | 35篇 |
1996年 | 41篇 |
1995年 | 29篇 |
1994年 | 23篇 |
1993年 | 20篇 |
1992年 | 6篇 |
1991年 | 6篇 |
1990年 | 6篇 |
1989年 | 24篇 |
1988年 | 14篇 |
1987年 | 8篇 |
1986年 | 16篇 |
1985年 | 22篇 |
1984年 | 10篇 |
1983年 | 11篇 |
1982年 | 12篇 |
1981年 | 8篇 |
1980年 | 11篇 |
1979年 | 5篇 |
1978年 | 8篇 |
1977年 | 5篇 |
1976年 | 7篇 |
1974年 | 3篇 |
1973年 | 3篇 |
1971年 | 2篇 |
排序方式: 共有916条查询结果,搜索用时 15 毫秒
31.
Bacigalupo A; Broccia G; Corda G; Arcese W; Carotenuto M; Gallamini A; Locatelli F; Mori PG; Saracco P; Todeschini G 《Blood》1995,85(5):1348-1353
Patients with severe aplastic anemia (SAA) and a neutrophil (PMN) count of less than 0.5 x 10(9)/L are exposed to a high risk of early mortality when treated with antilymphocyte globulin (ALG) and steroids, with the major problem being infectious complications. The addition of human recombinant granulocyte colony-stimulating factor (rhG-CSF) to ALG may reduce early mortality by improving neutrophil counts in the short term. To test the feasibility of this approach, the SAA Working Party of the European Group for Blood and Marrow Transplantation (EBMT) designed a pilot study that included rhG-CSF (5 micrograms/kg/d, days 1 through 90), horse ALG (HALG; 15 mg/kg/d, days 1 through 5), methylprednisolone (2 mg/kg/d, days 1 through 5, then tapering the dose), and cyclosporin A (CyA; 5 mg/kg/d orally, days 1 through 180). Patients with newly diagnosed acquired SAA (untreated) and with neutrophil counts of < or = 0.5 x 10(9)/L were eligible. Forty consecutive patients entered this study and are evaluable with a minimum follow up of 120 days: the median age was 16 years (range, 2 to 72 years), the interval from diagnosis to treatment was 24 days, and the median PMN count was 0.19 x 10(9)/L. Twenty-one patients had hemorrhages, and 19 were infected at the time of treatment. Overall, treatment was well tolerated: the median maximum PMN count during rhG- CSF administration was 12 x 10(9)/L (range, 0.4 x 10(9)/L to 44 x 10(9)/L). There were three early deaths (8%) due to infection. Four patients (10%) showed no recovery, whereas 33 patients (82%) had trilineage hematologic reconstitution and became transfusion- independent at a median interval of 115 days from treatment. Median follow up for surviving patients is 428 days (range, 122 to 1,005). Actuarial survival is 92%: 86% and 100% for patients with PMN counts less than 0.2 x 10(9)/L or between 0.2 x 10(9)/L and 0.5 x 10(9)/L, respectively. This study suggests that the addition of rhG-CSF to ALG and CyA is well tolerated, is associated with a low risk of mortality, and offers a good chance of hematologic response. This protocol would appear to be an interesting alternative treatment for SAA patients with a low PMN count who lack an HLA-identical sibling. 相似文献
32.
33.
Salma I. Mohammed MD FFPMRCA Sam Eldabe MD FFPMRCA Karen H. Simpson MD FFPMRCA Morag Brookes PG Dip Grace Madzinga Dip HE Ashish Gulve Ganesan Baranidharan MD FFPMRCA Helen Radford BHSc Tracey Crowther BSC Eric Buchser MD Christophe Perruchoud MD Alan Mark Batterham PhD 《Neuromodulation》2013,16(6):576-582
34.
35.
An evaluation of the ‘Yaka Ŋarali’’ Tackling Indigenous Smoking program in East Arnhem Land: Yolŋu people and their connection to ŋarali’
下载免费PDF全文
![点击此处可从《Health promotion journal of Australia》网站下载免费的PDF全文](/ch/ext_images/free.gif)
36.
37.
Robert W. McConkey RANP RNP MSc BSc PG Dip PG Cert Therese Kelly RANP RNP MSc PG Dip PG Cert Rachael Dalton RANP RNT RNP MSc BSc PG Dip Geraldine Rooney cANP RNP BSc PG Dip PG Cert Michelle Healy cANP BSc PG Cert Louise Murphy PhD BSc PG Dip RPN RNT Maura Dowling PhD MSc RGN RNT 《International Journal of Urological Nursing》2023,17(1):78-83
Evidence based practice is essential to advanced practice nursing, enabling the delivery of quality care and improved patient outcomes. As the name suggests, it requires healthcare decisions to be based on the best available and current evidence. Advanced practice nurses need astute critical analysis skills to appraise the evolving literature, and require research skills to lead on scientific inquiry and develop the profession. Yet, advanced practice nurses may not recognize themselves as research leaders. Participation in a journal club can promote evidence-based practice, improve clinician's critical thinking skills, and expose members to different research methodologies, however, nurses continue to face barriers to participation in these clubs. Establishing a clinical-academic partnership appears to be both mutually beneficial for clinicians and academics and is a significant enabler in the sustainability and functioning of the club through sharing expertise and experience. A supportive workplace culture is favourable to research utilization and knowledge translation. This paper outlines the role, practicalities, challenges, and benefits of setting up a hybrid urology journal and research club for advanced practice nurses in a clinical-academic partnership. 相似文献
38.
C Greenfield J R Aguilar Ramirez R E Pounder T Williams M Danvers S R Marper P Noone 《Gut》1983,24(8):713-717
Stools from 109 patients with inflammatory bowel disease (13.4%) contained Clostridium difficile or its toxin, an incidence similar to the stools of 99 control patients with diarrhoea (11.9%), but significantly higher than the stools of 77 control patients with a normal bowel habit (1.4%). Sixty-six per cent of the diarrhoea controls, but only 11% of the inflammatory bowel disease patients, reported recent antibiotic use: however, 67% of inflammatory bowel disease patients were taking sulphasalazine. The presence of Cl difficile in the stool was not related to the clinical assessment of inflammatory bowel disease relapse, but it was related to hospital admission. During the one year study, 31 of the 109 patients (28%) with inflammatory bowel disease had one or more stool samples that were positive for Cl difficile. 相似文献
39.
Effects of monoclonal antibody therapy in patients with chronic lymphocytic leukemia 总被引:4,自引:0,他引:4
Foon KA; Schroff RW; Bunn PA; Mayer D; Abrams PG; Fer M; Ochs J; Bottino GC; Sherwin SA; Carlo DJ 《Blood》1984,64(5):1085-1093
A phase I clinical trial was initiated to treat patients with stage IV B-derived chronic lymphocytic leukemia (CLL) with the IgG2a murine monoclonal antibody T101. This antibody binds to a 65,000-mol wt (T65) antigen found on normal T lymphocytes, malignant T lymphocytes, and B- derived CLL cells. All of the patients had a histologically confirmed diagnosis of advanced B-derived CLL and were refractory to standard therapy, and more than 50% of their leukemia cells reacted with the T101 antibody in vitro. The patients received T101 antibody two times per week, over two to 50 hours by intravenous administration in 100 mL of normal saline containing 5% human albumin. Twelve patients were treated with a fixed dosage of 1, 10, 50, or 100 mg, and one patient was treated with 140 mg of antibody. It was demonstrated that patients given two-hour infusions of 50 mg developed pulmonary toxicity, with shortness of breath and chest tightness. This toxicity was eliminated when infusions of 50 or 100 mg of T101 were prolonged to 50 hours. All dose levels caused a rapid but transient decrease in circulating leukemia cell counts. In vivo binding to circulating and bone marrow leukemia cells was demonstrated at all dose levels with increased binding at higher dosages. Antimurine antibody responses were not demonstrated in any patients at any time during treatment. Circulating free murine antibody was demonstrated in the serum of only the two patients treated with 100 mg of antibody as a 50-hour infusion and the patient treated with 140 mg of antibody over 30 hours. Antigenic modulation was demonstrated in patients treated at all dose levels but was particularly apparent in patients treated with prolonged infusions of 50 and 100 mg of antibody. We were also able to demonstrate antigenic modulation in lymph node cells, which strongly suggests in vivo labeling of these cells. Overall, T101 antibody alone appears to have a very limited therapeutic value for patients with CLL. The observations of in vivo labeling of tumor cells, antigenic modulation, antibody pharmacokinetics, toxicity, and antimurine antibody formation may be used in the future for more effective therapy when drugs or toxins are conjugated to the antibody. 相似文献
40.
ALI H.D. Alshehri Sarah O.S. Osman Kevin M. Prise Caoimhghin Campfield PG Turner Suneil FRCR PhD Jain Joe M. OSullivan Aidan J. Cole 《The British journal of radiology》2020,93(1115)
Objectives:The isotope bone scan (IBS) is the gold-standard imaging modality for detecting skeletal metastases as part of prostate cancer staging. However, its clinical utility for assessing skeletal metastatic burden is limited due to the need for subjective interpretation. We designed and tested a novel custom software tool, the Metastatic Bone Scan Tool (MetsBST), aimed at improving interpretation of IBSs, and compared its performance with that of an established software programme.Methods:We used IBS images from 62 patients diagnosed with prostate cancer and suspected bone metastases to design and implement MetsBST in MATLAB by defining thresholds used to identify the texture and size of metastatic bone lesions. The results of MetsBST were compared with those of the commercially available automated Bone Scan Index (aBSI) with regression analysis.Results:There was strong agreement between the MetsBST and aBSI results (R2 = 0.9189). In a subregional analysis, MetsBST quantified the extent of metastatic disease in multiple bone sites in patients receiving multimodality therapy (radium-223 and external beam radiotherapy) to illustrate the differences in bone metastatic response to different treatments.Conclusion:The results of MetsBST and the commercial software aBSI were highly consistent. MetsBST introduces novel clinical utility by its ability to differentiate between the responses of different bone metastases to multimodality therapies.Advances in knowledge:MetsBST reduces the variability in assessment of tumour burden caused by subjective interpretation. Therefore, it is a useful aid to physicians reporting nuclear medicine scans, and may improve decision-making in the treatment of metastatic prostate cancer. 相似文献